World's Best Scientists 2026 revealed!
Drugs of Today
H-index 10

Drugs of Today

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Medicine 2598 20 26 9

Additional Metrics

Number of Best Scientists*: 31
Documents by Best Scientists*: 46
Top 100 Ranked Scientists*: 2
SCIMAGO H-index: 59
SCIMAGO SJR: 0.492
Impact Factor: N/A

Overview

Top Research Topics at Drugs of Today?

Drugs of Today tackles a plethora of topics, such as Internal medicine, Pharmacology, Disease, Clinical trial and Intensive care medicine. Drugs of Today explores topics in Internal medicine which can be helpful for research in disciplines like Gastroenterology, Endocrinology, Oncology and Cardiology. It tackles issues in Pharmacology, particularly in the topics of Adverse effect, Drug, Pharmacokinetics and Tolerability.

The journal features Disease research that overlaps with concepts in Immunology. The majority of Immunology studies presented zero in on Immune system. The research on Cancer discussed in the journal draws on the closely related field of Cancer research.

  • Internal medicine (27.15%)
  • Pharmacology (20.56%)
  • Disease (10.48%)

What are the most cited papers published in the journal?

  • Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. (207 citations)
  • Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. (181 citations)
  • Wound healing: the role of growth factors. (175 citations)

Research areas of the most cited articles at Drugs of Today:

The most cited publications investigate areas of study like Pharmacology, Internal medicine, Cancer research, Endocrinology and Immunology. Many of the studies tackled in the journal publications connect Pharmacology with a similar field of study like Receptor. The Internal medicine research tackled in the journal papers is interrelated with Oncology which concerns subjects like Chemotherapy.

What topics the last edition of the journal is best known for?

  • Internal medicine
  • Disease
  • Cancer

The previous edition focused in particular on these issues:

The aim of the journal is to expand the discussion of research in Internal medicine, Clinical trial, Oncology, Virology and Disease. The journal held discussions to help close the divide between two different fields of study: Internal medicine and English language. Drugs of Today addresses concerns in Oncology which are intertwined with other disciplines, such as Chimeric antigen receptor, Multiple myeloma, Phases of clinical research and Daratumumab.

The featured Disease studies mainly concentrate on Pediatrics but also cover areas of interest in Chagas disease and Tropical disease. It holds forums on Dravet syndrome that merges themes from other disciplines such as Placebo and Pharmacology. The studies on Pharmacology discussed can also contribute to research in the domains of Agonist, Pathophysiology and Monoclonal antibody.

The most cited articles from the last journal are:

  • Dostarlimab for the treatment of endometrium cancer and other solid tumors. (3 citations)
  • Givosiran to treat acute porphyria. (2 citations)
  • Update on nifurtimox for treatment of Chagas disease. (1 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Drugs of Today (based on the number of publications) are:

  • Xavier Rabasseda (75 papers) absent at the last edition,
  • Jordi Gras (40 papers) absent at the last edition,
  • Antonio Jimeno (36 papers) published 1 paper at the last edition, 3 less than at the previous edition,
  • Richard T. Owen (30 papers) absent at the last edition,
  • David M. Paton (24 papers) published 4 papers at the last edition, 1 more than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Drugs of Today (based on the number of publications) are:

  • Thomson Reuters (124 papers) absent at the last edition,
  • Mayo Clinic (42 papers) absent at the last edition,
  • University of Colorado Denver (31 papers) published 1 paper at the last edition, 1 less than at the previous edition,
  • University of Auckland (20 papers) published 3 papers at the last edition, 2 more than at the previous edition,
  • Harvard University (18 papers) absent at the last edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 34.09% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 24.14% were posted by at least one author from the top 10 institutions publishing in the journal. Another 10.34% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 13.79% of all publications and 51.72% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Opportunities in Medical Research

The field of medical research extends far beyond the academic realm and offers various opportunities across different sectors, including biotechnology, pharmaceuticals, healthcare systems, and governmental agencies. Many individuals who dedicate their careers to medical research often start with a background in nursing or other healthcare professions. For those who are considering a career in this field, understanding individual state requirements and costs for licensure may be helpful. For instance, you can learn about the west virginia nursing license requirements and nursing license cost.

Beyond getting licensure, a research-minded medical professional may want to specialize in areas such as genetics, neuroscience, or drug discovery. They may also choose to focus on particular health conditions like cancer or neurological disorders. The work frequently involves conducting clinical trials, developing new therapies, or contributing to public health initiatives.

Every medical research career starts with a solid education and thorough preparation. On top of nursing or medical degrees, advanced degrees such as a Master’s or PhD in a specific scientific field may allow individuals to dive deeper into the medical research they are most passionate about. Therefore, the career pathway is certainly challenging, but it is also full of new discoveries and chances to make valuable contributions to global health.

Top Publications

  • Givosiran to treat acute porphyria.

    (2021)
    30 Citations
  • Oliceridine, a G protein-selective ligand at the μ-opioid receptor, for the management of moderate to severe acute pain.

    T.J. Gan;L. Wase

    (2020)
    24 Citations
  • L-Glutamine in sickle cell disease.

    S.E. Cox;E. Hart;F.J. Kirkham;H. Stotesbury

    (2020)
    19 Citations
  • Nemolizumab for atopic dermatitis

    (2022)
    14 Citations
  • Mirogabalin besylate in the treatment of neuropathic pain.

    J. Burgess;Saad Javed;B. Frank;Rayaz A. Malik

    (2020)
    13 Citations
  • Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.

    Sandro M. Wagner;Thomas Melchardt;Richard F. Greil

    (2020)
    11 Citations
  • Dostarlimab for the treatment of endometrium cancer and other solid tumors.

    J Rubio-Pérez;R Hernández;T Hernández;B Doger

    (2021)
    10 Citations
  • Ibrexafungerp for the treatment of vulvovaginal candidiasis.

    (2022)
    9 Citations
  • Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors.

    S. Marsh;Antonio Jimeno

    (2020)
    9 Citations
  • Melphalan flufenamide for relapsed/refractory multiple myeloma.

    (2022)
    8 Citations

Related Online Degrees & Career Pathways

For those interested in the medical field but exploring alternatives to traditional medical school, several online degree options offer flexible and affordable pathways. Nursing is a popular choice, and many candidates seek programs that reduce entry barriers. Schools offering nursing school without teas or other standardized entrance exams provide a streamlined admissions process.

Healthcare administration is another vital area within medicine, focusing on managing healthcare systems and policies. Pursuing a master of healthcare administration online allows professionals to enhance their leadership skills and career prospects without disrupting their current roles.

For those looking to start clinical work sooner, online lpn programs provide an accelerated path to becoming a Licensed Practical Nurse. These programs balance practical training with flexible online coursework, making them ideal for career changers or busy students.

Advanced academic options like the phd nursing education online open doors to research, teaching, and leadership roles. These programs emphasize advanced nursing theory, research methodologies, and education techniques, supporting career growth beyond clinical practice.

Best Scientists Contributing to This Journal

Recently Published Articles